Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of Zidovudine, Lamivudine, and Ritonavir: Results of AIDS clinical trials group protocol 315

Journal of Infectious Diseases

Volumn 178, Issue 1, 1998, Pages 70-79

  Lederman, Michael M ^a   Connick, Elizabeth ^c   Landay, Alan ^c   Kuritzkes, Daniel R ^c   Spritzler, John ^c   Clair, Marty St ^c   Kotzin, Brian L ^c   Fox, Lawrence ^c   Chiozzi, Margo Heath ^c   Leonard, John M ^c   Rousseau, Franck ^b   Wade, Michael ^c   Roe, Joana D'Arc ^c   Martinez, Ana ^c   Kessler, Harold ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Triangle Institute   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; RITONAVIR; T LYMPHOCYTE RECEPTOR; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG EFFECT; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SKIN TEST; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

EID: 17344365057     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515591     Document Type: Article

References (26)

1. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men; evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981;305:l425-31.
2. Mildvan D, Mathur U, Enlow RW, et al. Opportunistic infections and immune deficiency in homosexual men. Ann Intern Med 1982;96:700-4.
3. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985:313:79-84.
4. + cell numbers and clinical staging. J Clin Invest 1989;84:1892-9.
5. Birx DL, Brundage J, Larson K, et al. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. J Acquir Immune Defic Syndr 1993;6:1248-57.
6. + T cell subset phenotyping independently predict survival time in patients infected with the human immunodeficiency virus. J Infect Dis 1995;172:79-87.
7. Imberti L, Sottini A, Bettinardi A, Puoti M, Primi D. Selective depletion in HIV infection of T cells that bear specific T cell receptor Vβ sequences. Science 1991;254:860-2.
8. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997:3:533-40.
9. + levels: results of 6 years of follow up. J Acquir Immune Defic Syndr 1993;6:904-12.
10. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996:384:529-34.
11. Lederman MM, Carey JT, Purvis S. Autologous killing by lymphocytes of persons infected by the human immunodeficiency virus. In: Andrieu JM, Bach JF, Even P, eds. Autoimmune aspects of HIV infection. London: Royal Society of Medicine Services, 1988:165-74.
12. + cells. J Immunol 1990;144:2992-8.
13. Aukrust P, Liabakk NB, Muller F, Lien E, Espevik T, Froland SS. Serum levels of tumor necrosis factor (TNF)-α and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic and virologie parameters. J Infect Dis 1994; 169:420-4.
14. Dezube BJ, Lederman MM, Chapman B, et al. The effect of Tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels. J Infect Dis 1997;176: 807-10.
15. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:247-57.
16. Cameron DW, Heath-Chiozzi M, Kravick S, Mills R, Potthoff A, Henry D. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with Ritonavir: update [abstract]. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada). Vancouver: Xi International Conference on AIDS Society, 1996.
17. Thompson NJ, Glasroth J, Sinder D, Farer L. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979;119:587-97.
18. Sokal JE. Measurement of delayed skin-test responses. N Engl J Med 1975;293:501-2.
19. Pouchot J, Grasland A, Collet C, Coste J, Esdalie JM, Vinceneux P. Reliability of tuberculin skin test measurement. Ann Intern Med 1997; 126:210-4.
20. AIDS Clinical Trials Group Immunology Laboratory Committee Consensus Methodologies. Bethesda, MD: NIH, 1997; http://aactg.s-3.com.
21. Posnett DN, Romagne F, Necker A, Kotzin BL, Sekaly RP. Summary: first human TCR monoclonal antibody workshop. Immunologist 1996; 4:5-8.
22. Van Gemen B, van Beuningen R, Nabbe A, et al. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electro-chemiluminescent (ECL) labelled probes. J Virol Methods 1996;49: 157-68.
23. Lederman M, Connick E, Landay A, et al. Partial immune reconstitution after 12 weeks of HAART (AZT, 3TC, Ritonavir) Preliminary Results of ACTG 315 [abstract]. In: 4th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1997.
24. Pagano M, Gauvreau K. Principles of biostatistics. Belmont, CA: Duxbury Press, 1993:263.
25. Lehman EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975:123, 268-9, 55-65.
26. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, Herzenberg LA. CDS naive T cells decrease progressively in HIV-infected adults. J Clin Invest 1995;95:2061-6.